Concepts (67)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Haemophilus Infections | 1 | 2023 | 15 | 0.850 |
Why?
|
| Mycoplasma | 1 | 2023 | 9 | 0.850 |
Why?
|
| Bronchiolitis | 1 | 2023 | 17 | 0.850 |
Why?
|
| Carcinoma | 2 | 2003 | 117 | 0.240 |
Why?
|
| Colorectal Neoplasms | 1 | 2002 | 262 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2004 | 327 | 0.090 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 32 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2004 | 132 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2004 | 80 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2003 | 74 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2002 | 7 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2002 | 8 | 0.050 |
Why?
|
| Genes, APC | 1 | 2002 | 10 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 200 | 0.050 |
Why?
|
| Tubulin | 1 | 2002 | 74 | 0.050 |
Why?
|
| Japan | 1 | 2002 | 57 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 239 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2002 | 104 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 465 | 0.040 |
Why?
|
| Humans | 4 | 2023 | 60132 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2002 | 225 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 405 | 0.040 |
Why?
|
| Mutation | 1 | 2002 | 2471 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2004 | 77 | 0.030 |
Why?
|
| Probability | 2 | 2004 | 173 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2004 | 558 | 0.030 |
Why?
|
| Prognosis | 2 | 2004 | 1591 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2004 | 1937 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 61 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 75 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 209 | 0.010 |
Why?
|
| Etoposide | 1 | 2003 | 35 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2004 | 47 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2003 | 49 | 0.010 |
Why?
|
| Gastrectomy | 1 | 2003 | 38 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 361 | 0.010 |
Why?
|
| Cisplatin | 1 | 2003 | 119 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2004 | 5262 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2003 | 99 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2003 | 72 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 129 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 177 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2003 | 233 | 0.010 |
Why?
|
| Nocodazole | 1 | 2002 | 15 | 0.010 |
Why?
|
| Enterocytes | 1 | 2002 | 25 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 679 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 73 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 577 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 460 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 454 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 854 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 1035 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1100 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 1158 | 0.010 |
Why?
|
| Male | 3 | 2004 | 27971 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 847 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1566 | 0.010 |
Why?
|
| Aged | 2 | 2004 | 13581 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 2479 | 0.010 |
Why?
|
| Female | 3 | 2004 | 31250 | 0.010 |
Why?
|
| Adult | 2 | 2004 | 15985 | 0.010 |
Why?
|
| Middle Aged | 2 | 2004 | 16535 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 3218 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 5197 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2004 | 6139 | 0.010 |
Why?
|
| Mice | 1 | 2002 | 10343 | 0.000 |
Why?
|
| Animals | 1 | 2002 | 19768 | 0.000 |
Why?
|